Hyphens Pharma International Ltd. (SG:1J5) has released an update.
Hyphens Pharma International Ltd., a prominent Singapore-based specialty pharmaceutical firm, has secured an exclusive deal with MC2 Therapeutics to bring Wynzora Cream, a treatment for plaque psoriasis, to the ASEAN market. Wynzora Cream, already approved in several major markets including the US and various European countries, represents a significant expansion of Hyphens Pharma’s dermatological portfolio in Southeast Asia.
For further insights into SG:1J5 stock, check out TipRanks’ Stock Analysis page.
